Zavadsky VN*

Department of Skin and Venereal Diseases of the Yaroslavl State Medical Academy, Russia

*Corresponding Author: Zavadsky VN, Department of Skin and Venereal Diseases of the Yaroslavl State Medical Academy, Russia.

Received: January 18, 2023; Published: February 14, 2023

Abstract

Pulse immunomodulatory mesotherapy (PIMT) for mild and moderate forms of psoriasis is described. A suspension of a prolonged-acting glucocorticoid in a mini-dose - betamethasone 7 mg (or triamcinolone 40 mg) - is diluted with a saline solution of sodium chloride, 10-15 mg of methotrexate is added as an injection solution, and this mixture of drugs is injected intradermally into the lesions 1 time per month. The effectiveness of PIMT in psoriasis, which is an immune-dependent chronic disease, has been shown. PIMT is a convenient alternative to local corticosteroids - for the treatment of adults, adolescents and partly children. With a mild course of psoriasis, PIMT has a sufficient and pathogenetic effect. Advantages of PIMT: treatment is carried out no more than 1 time per month, simultaneously; the effect is manifested from the first days, stable; relapses become less frequent and weaker; the total dose of glucocorticoid with PIMT is no more (even less) than required with external corticosteroid therapy; the safety of PIMT is ensured by an acceptable fixed dose of the drug and its reliable natural decrease. Quality of life is improving (service and management are higher): the "ointment dependence" has been eliminated, the procedures are rare, not burdensome; temporary disability is reduced, hospitalization is not required. There is an economic benefit.

Keywords: Psoriasis; Pulse Immunomodulatory Mesotherapy; Mini-Dose of Glucocorticoid; Quality of Life

References

1. Albert A. “Selektive toxicity. The physico-chemical basis of therapy”. 7^th ed, - Chapman and Hall. - London, N.-Y 1(1985).
2. Valencia IC and Kerdel FA. “Local corticosteroids”. In: Fitzpatrick’s Dermatology in General Medicine/Wolff K., Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J. - McGraw Companies. - N.-Y., Chicago, London., et al., (2008).
3. Zavadsky VN. “Pulse mesotherapy of immunoassociated dermatoses”. Russian Journal of Skin and Venereal Diseases 5(2014): 31-35.
4. Krueger GG., et al. “Medical Advisory Board of the National Psoriasis Foundation/A new scoring system to determine if clinically significant improvement has occurred in clinical trials that assess the effect of therapy on psoriasis”. Psoriasis Forum1(2002): 3-4.
5. Weber E. “Grundriss der biologischen Statistik fűr Naturwissenschaftler, Landwirte und Mediziner. – 4. Auflage.- VEB G.Fischer Verlag, - Jena, (1961): 515-521
6. Roenigk HH. “Methotrexate in psoriasis: consensus conference”. Journal of the American Academy of Dermatology 38(1998): 478-485.

Citation

Citation: Zavadsky VN. “Pulse Immunomodulatory Mesotherapy of Psoriasis”.Acta Scientific Medical Sciences 7.3 (2023): 109-112.

Copyright

Copyright: © 2022 Zavadsky VN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.